Central Nervous System Lymphoma
📧 Sign up to get email alerts when something new happens for Central Nervous System Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma [Phase 2]
Phase 2 clinical trial update investigating thiotepa in combination with pirtobrutinib and sintilimab for frail or relapsed/refractory prima…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) [Phase 1]
Phase 1 trial evaluating the combination of epcoritamab and ibrutinib in patients with central nervous system lymphomas, sponsored by Memori…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. [Phase 2]
A Phase 2 clinical trial is evaluating a PD-1 inhibitor in combination with Rituximab, Methotrexate, and Orelabrutinib for newly diagnosed P…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Methotrexate Early Toxicity Monitoring [NA]
A clinical trial update on early toxicity monitoring for methotrexate in patients with Primary central nervous system lymphoma; the trial st…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma [Phase 2]
This clinical trial entry reports a Phase 2 study evaluating zanubrutinib in combination with chemotherapy for newly diagnosed central nervo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the combination of copanlisib and ibrutinib in patients with refractory or recurrent primary central n…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Real World Data on Ibrutinib Use in PCNSL Rel/Ref
Real-world data study update on the use of ibrutinib in relapsed or refractory primary central nervous system lymphoma.
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the BTK inhibitor ibrutinib in adults with newly diagnosed or relapsed/refractory primary CNS lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) [Phase 1]
Phase 1 study evaluating the combination of ibrutinib, rituximab, and lenalidomide in patients with recurrent/refractory primary central ner…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy [Phase 2]
This Phase 2 clinical trial assessed nivolumab as maintenance therapy in newly diagnosed primary central nervous system lymphoma with persis…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating combination chemotherapy with or without autologous stem cell transplant for primary central nervous syste…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Tisagenlecleucel In Primary CNS Lymphoma [Phase 1]
This update covers a Phase 1 study of tisagenlecleucel in primary central nervous system lymphoma, including refractory/relapsed cases, whic…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
This trial update reports on pharmacogenomics effects on the clearance of high-dose methotrexate in patients with diffuse large B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma [Phase 1]
A Phase 1 trial evaluating nivolumab as consolidation therapy in older adults (≥65) with primary central nervous system lymphoma has complet…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients [Phase 1]
Phase 1 study assessing safety and tolerability of CD19x22 CAR T cells in adolescents and adults with relapsed/refractory B-cell non-Hodgkin…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) [Phase 2]
Phase 2 clinical trial TEDDI-R evaluating a combination of temozolomide, etoposide, liposomal doxorubicin (Doxil), dexamethasone, ibrutinib,…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma [Phase 2]
Phase 2 trial evaluating Anbalcabtagene Autoleucel for relapsed/refractory primary central nervous system lymphoma and diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) [Phase 1]
Phase 1 trial SOLAR is evaluating loncastuximab tesirine in combination with rituximab following stereotactic radiosurgery for central nervo…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
A recruiting clinical study examining metabolic and immunomic differences in primary central nervous system lymphoma and diffuse large B-cel…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma [Phase 1]
A phase 1 clinical trial is evaluating glofitamab with obinutuzumab pre-treatment for primary or secondary central nervous system lymphoma, …
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS other · 2025-11-10Clinical Trial Update: Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
This clinical trial is evaluating neurocognitive outcomes after whole brain radiation therapy in patients with CNS lymphoma and other hemato…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial [Phase 2]
This Phase IIc randomized feasibility pilot trial evaluated cognitive behavioral therapy for insomnia in patients with primary brain tumors …
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma [NA]
This clinical trial update describes a forthcoming study evaluating a combination regimen of Relmacabtagene autoleucel CAR-T cells, autologo…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) [Phase 1, Phase 2]
A clinical trial update for GNC-038, a tetra-specific antibody, in primary central nervous system lymphoma and relapsed or refractory second…